Latest From Tolerion Inc.
A vaccine that can prevent the damage to pancreatic β-cells in patients with type I diabetes has long been the Holy Grail of diabetes research.
It is now almost 20 years since the first patient was enrolled into an officially sanctioned gene therapy study, and in that time the field has been through a series of successes and setbacks. Today, it remains the case that only two gene therapy products have ever been approved anywhere in the world, but interest in gene therapy remains keen.
Versartis (US), an emerging biotechnology company developing therapeutics for metabolic diseases and endocrine disorders, has appointed Paul Westberg senior vice-president of business development. He was most recently vice-president of business development at Bayhill Therapeutics, and has also worked at Collabra Pharma, Deltagen and Genentech. Versartis is planning to initiate its first clinical trial of its lead product candidate VRS-859 in type 2 diabetes in the second half and to have top-line results by the end of the year.
Genentech is to pay the US private biopharmaceutical company Bayhill Therapeutics $25 million up-front and potential milestones of more than $325 million to develop and commercialise BHT-3021, a DNA-based antigen specific immunotherapy in Phase I/II clinical trials in patients with type 1 diabetes.
- Therapeutic Areas
- Immune Disorders
- Bayhill Therapeutics Inc.
- North America
- Parent & Subsidiaries
- Tolerion Inc.
- Senior Management
- Contact Info
Phone: (650) 575-1702
321 Dedalera Dr.
Portola Valley, CA 94028
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.